targeted treatment with egfr tkis: front line options
Published 5 years ago • 3.3K plays • Length 20:24Download video MP4
Download video MP3
Similar videos
-
17:55
front-line targeted therapy for advanced egfr-positive disease
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
10:06
debate: what is the optimal timing for egfr-targeted therapy? - favor frontline therapy
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
10:05
debate: what is the optimal timing for egfr-targeted therapy? - favor maintenance
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
33:52
keynote lecture: targeted therapies in lung cancer 2.0 – advances and promises
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
20:35
tki-resistant egfr-mutant nsclc
-
22:10
first and second generation alk inhibitors for the treatment of lung cancer
-
8:28
upfront egfr-targeted therapy
-
2:26
additional egfr-tki therapy research in nsclc
-
2:34
egfr-tkis in first-line egfr metastatic nsclc
-
6:23
frontline chemo and tki combination in egfr nsclc
-
5:47
egfr tkis for upfront treatment of nsclc
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?